This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB PHARMA Inc. (US)
Study access was limited to subjects having completed one of the previous brivaracetam (BRV) studies: N01193 \[NCT00175825\], N01252 \[NCT00490035\], N01253 \[NCT00464269\], N01254 \[NCT00504881\].
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male/ female subjects from 16 years and on. Subjects under 18 years may only be included where legally permitted and ethically accepted
Subjects with epilepsy who have participated in previous brivaracetam trials which allow access to the present study
Subjects for whom the investigator believes a reasonable benefit from the long term administration of brivaracetam may be expected
Subject/ legally acceptable representative considered as reliable and capable of adhering to the protocol, visit schedule or medication intake according to the judgment of the Investigator
You may not be if
Severe medical, neurological and psychiatric disorders or laboratory values which may have an impact on the safety of the subject
Poor compliance with the visit schedule or medication intake in the previous brivaracetam study
Pregnant or lactating women
Participation in any clinical study of another investigational drug or device during the study
Clareo Health | This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment
